Download PDF
Z Gastroenterol 2009; 47(5): 436-445
DOI: 10.1055/s-0028-1109200
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Der hepatogene Diabetes – aktueller Stand der Diagnostik und Therapie

Hepatogenous Diabetes – Diagnostics and TreatmentF. Gundling1 , P. M. Schumm-Draeger2 , W. Schepp1
  • 1II. Medizinische Abteilung, Städtisches Krankenhaus München-Bogenhausen
  • 2III. Medizinische Abteilung, Städtisches Krankenhaus München-Bogenhausen
Further Information

Publication History

Manuskript eingetroffen: 13.3.2008

Manuskript akzeptiert: 14.1.2009

Publication Date:
05 May 2009 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Hintergrund: Patienten mit Leberzirrhose entwickeln häufig Störungen des Glukosemetabolismus wie Glukoseintoleranz oder einen hepatogenen Diabetes, welche neben der hepatozellulären Funktionseinschränkung durch die ausgeprägte Insulinresistenz als Folge der chronischen Lebererkrankung verursacht sind. Diskussion: Empfehlungen mit Leitliniencharakter zur Diagnostik und Therapie des hepatogenen Diabetes fehlen bislang. Im Hinblick auf basistherapeutische Maßnahmen sollte eine ausreichende Deckung des Energie- und Proteinstoffwechsels gewährleistet sein, da ein Großteil der Zirrhosepatienten mangelernährt ist. Bei der medikamentösen Behandlung des hepatogenen Diabetes muss auf die erhöhte Hypoglykämie-Gefährdung geachtet werden. Aufgrund der Nebenwirkungen sind Biguanide sowie PPAR-gamma-Liganden bei Leberzirrhose kontraindiziert. Geeignete orale Antidiabetika sind insbesondere Sulfonylharnstoffanaloga und kurz wirksame Sulfonylharnstoffe. Wenn eine suffiziente Diabetes-Einstellung mit oralen Antidiabetika nicht gelingt, sollte eine prandiale Insulintherapie mit Insulinen von kurzer Wirkdauer oder kurz wirksamen Insulinanaloga eingesetzt werden. Schlussfolgerung: Die Optimierung einer diabetischen Stoffwechsellage hat neben der Vermeidung typischer diabetischer Spätkomplikationen eine wichtige Bedeutung für die Vermeidung und Reduzierung von Zirrhose-assoziierten Komplikationen, wie z. B. gastrointestinale Blutungsereignisse, hepatische Enzephalopathie oder das Auftreten eines hepatozellulären Karzinoms.

Abstract

Background: Patients with liver cirrhosis develop frequently disturbances of glucose metabolism e. g. glucose intolerance or hepatogenous diabetes which are caused by the hepatocellular functional loss and insulin resistance due to chronic liver disease. Discussion: Until now there are no recommendations comparable to guidelines on the diagnosis of and therapy for hepatogenic diabetes. Regarding basic treatment a sufficient daily energy and protein supply should be guaranteed since the majority of patients with liver cirrhosis are malnourished. The risk of hypoglycaemia must be considered carefully under pharmacological treatment of hepatogenous diabetes. Biguanide and PPAR gamma agonists are contraindicated due to side effects in liver cirrhosis. Suitable oral antidiabetics are glinides and short-acting sulfonylureas. If a sufficient diabetes adjustment does not succeed by oral antidiabetics a prandial insulin therapy using short-acting insulins or rapid-acting insulin analogues should be applied. Conclusion: Optimisation of diabetic metabolic conditions is not only important to avoid typical diabetic late complications but also cirrhosis-associated complications, e. g., gastrointestinal bleeding, hepatic encephalopathy or the occurrence of hepatocellular carcinoma.

Schlüsselwörter

Leber - Diabetes - Glukosestoffwechselstörungen

Key words

liver - diabetes - glucose metabolism dysfunction

Literatur

  • 1 AlDosary A A, Ramji A S, Elliott T G. et al . Post-liver transplantation diabetes mellitus: an association with hepatitis C.  Liver transp. 2002;  8 356-361
    Google Scholar
  • 2 Baggio L L, Drucker D J. Biology of incretins: GLP-1 and GIP.  Gastroenterology. 2007;  132 2131-2157
    Google Scholar
  • 3 Bianchi G P, Marchesini G, Fabbri A. et al . Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison.  J Intern Med. 1993;  233 385-392
    Google Scholar
  • 4 Bosch J, Gomis R, Kravetz D. et al . Role of spontaneous portal-systemic shunting in hyperinsulinism of cirrhosis.  Am J Physiol. 1984;  247 G206-G212
    Google Scholar
  • 5 Campillo B, Paillaud E, Uzan I. et al . Value of body mass index in the detection of severe malnutrition: influence of the pathology and changes in anthropometric parameters.  Clin Nutr. 2004;  23 551-559
    Google Scholar
  • 6 Caronia S, Taylor K, Pagliaro L. et al . Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection.  Hepatology. 1999;  30 1059-1063
    Google Scholar
  • 7 Chupin M, Charbonnel B, Le Bodic L. et al . Glucose tolerance in viral hepatitis. A study of twenty patients during the acute phase and after recovery.  Diabetes. 1978;  27 661-669
    Google Scholar
  • 8 Creutzfeldt W, Sickinger K, Frerichs H. Diabetes und Lebererkrankungen. Pfeiffer EF Handbuch des Diabetes mellitus München; Lehmann 1971 Vol. 2: 807-859
    Google Scholar
  • 9 Drucker D J, Nauck M A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.  Lancet. 2006;  368 1696-1705
    Google Scholar
  • 10 El-Serag H B, Tran T, Everhart J E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.  Gastroenterology. 2004;  126 460-468
    Google Scholar
  • 11 Empen K. Diabetes mellitus. Göke B, Parhofer K, Otto C München; Urban & Fischer Verlag 2002: 3-11
    Google Scholar
  • 12 Ferenci P, Lockwood A, Mullen K. et al . Hepatic encephalopathy – definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998.  Hepatology. 2002;  35 716-721
    Google Scholar
  • 13 Geiss H C. Diabetes mellitus. Göke B, Parhofer K, Otto C München; Urban & Fischer Verlag 2002: 15-39
    Google Scholar
  • 14 Gentile S, Guarino G, Romano M. et al . A randomized controlled trial of acarbose in hepatic encephalopathy.  Clin Gastroenterol Hepatol. 2005;  3 184-191
    Google Scholar
  • 15 Gentile S, Loguercio C, Marmo R. et al . Incidence of altered glucose tolerance in liver cirrhosis.  Diabetes Res Clin Pract. 1993;  22 37-44
    Google Scholar
  • 16 Gentile S, Turco S, Guarino G. et al . Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis.  Diabetes Obes Metab. 2001;  3 33-40
    Google Scholar
  • 17 Göke B. Diabetes mellitus. Göke B, Parhofer K, Otto C München; Urban & Fischer Verlag 2002: 61-74
    Google Scholar
  • 18 Greco A V, Mingrone G, Mari A. et al . Mechanisms of hyperinsulinaemia in Child’s disease grade B liver cirrhosis investigated in free living conditions.  Gut. 2002;  51 870-875
    Google Scholar
  • 19 Häring H, Joost H, Labe H. et al . Antihyperglykämische Therapie des Diabetes mellitus Typ 2. Evidenzbasierte Diabetes-Leitlinie DDG.  Diab Stoffw. 2003;  12 13-31
    Google Scholar
  • 20 Holman R R, Cull C A, Turner R F. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U. K. Prospective Diabetes Study 44).  Diabetes Care. 1999;  22 960-964
    Google Scholar
  • 21 Holstein A, Hinze S, Thiessen E. et al . Clinical implications of hepatogenous diabetes in liver cirrhosis.  Gastroenterol Hepatol. 2002;  17 677-681
    Google Scholar
  • 22 Huo T I, Lui W Y, Huang Y H. et al . Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study.  Am J Gastroenterol. 2003;  98 2293-2298
    Google Scholar
  • 23 Huo T I, Wu J C, Lee P C. et al . Diabetes mellitus as a risk factor of liver cirrhosis in patients with chronic hepatitis B virus infection.  J Clin Gastroenterol. 2000;  30 250-254
    Google Scholar
  • 24 Imano E, Nishida T, Shibata M. et al . Significance of Oral Glucose Tolerance Test for the Diagnosis of Diabetes mellitus in Patients with Liver Cirrhosis.  Int Med. 1999;  38 918
    Google Scholar
  • 25 Kaczynski J, Hansson G, Wallerstedt S. Diabetes: one of few remarkable differences in clinicopathologic features between cirrhotic and noncirrhotic Swedes with hepatocellular carcinoma.  Dig Dis Sci. 2006;  51 796-802
    Google Scholar
  • 26 Kihara Y, Ogami Y, Tabaru A. et al . Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose.  J Gastroenterol. 1997;  32 777-782
    Google Scholar
  • 27 Knobler H, Schattner A. TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad.  QJM. 2005;  98 1-6
    Google Scholar
  • 28 Knobler H, Stagnaro-Green A, Wallenstein S. et al . Higher incidence of diabetes in liver transplant recipients with hepatitis C.  J Clin Gastroenterol. 1998;  26 30-33
    Google Scholar
  • 29 Krauns P, Ruge W. Plasma catecholamine levels in liver disease.  Z Gastroenterol. 1985;  23 64-73
    Google Scholar
  • 30 Laubner K, Seufert J. Pharmaceutical therapy of diabetes mellitus type 2.  Internist. 2007;  48 297-310
    Google Scholar
  • 31 La V ecchia C, Negri E, Decarli A. et al . Diabetes mellitus and the risk of primary liver cancer.  Int J Cancer. 1997;  73 204-207
    Google Scholar
  • 32 Lawson D H, Gray J M, McKillop C. et al . Diabetes mellitus and primary hepatocellular carcinoma.  Q J Med. 1986;  61 945-955
    Google Scholar
  • 33 Leslie W D, Bernstein C N, Leboff M S. et al . AGA Technical Review on Osteoporosis in Hepatic Disorders.  Gastroenterology. 2003;  125 941-966
    Google Scholar
  • 34 Lochs H, Plauth M. Liver cirrhosis: rationale and modalities for nutritional support – the European Society of Parenteral and Enteral Nutrition consensus and beyond.  Curr Opin Clin Nutr Metab Care. 1999;  2 345-3494
    Google Scholar
  • 35 Mason A L, Lau J YN, Hoang N. et al . Association of diabetes mellitus and chronic hepatitis C virus infection.  Hepatology. 1999;  29 328-333
    Google Scholar
  • 36 McCullough A J, Bugianesi E. Protein-calorie malnutrition and the etiology of cirrhosis.  Am J Gastroenterol. 1997;  92 734-738
    Google Scholar
  • 37 Mehta S H, Brancati F L, Sulkowski M S. et al . Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States.  Ann Intern Med. 2000;  17 (133) 592-599
    Google Scholar
  • 38 Megeysi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease.  Lancet. 1967;  18 (2) 1051-1056
    Google Scholar
  • 39 Moradpour D. Klinische Pathophysiologie,. Siegenthaler, Blum Georg Thieme Verlag 859-869
    Google Scholar
  • 40 Moreau R, Chagneau C, Heller J. Hemodynamic, metabolic and hormonal responses to oral glibenclamide in patients with cirrhosis receiving glucose.  Scand J Gastroenterol. 2001;  36 303-308
    Google Scholar
  • 41 Moreau R, Delegue P, Pessione F. et al . Clinical characteristics and outcome of patients with cirrhosis and refractory ascites.  Liver Int. 2004;  24 457-464 xxx
    Google Scholar
  • 42 Moscatiello S, Manini R, Marchesini G. Diabetes and liver disease: an ominous association.  Nutr Metab Cardiovasc Dis. 2007;  17 63-70
    Google Scholar
  • 43 Moschen A R, Kaser A, Stadlmann S. et al . The RANKL/OPG system and bone mineral density in patients with chronic liver disease.  J Hepatol. 2005;  43 973-983
    Google Scholar
  • 44 Müller M J, Pirlich M, Balks H J. et al . Glucose intolerance in liver cirrhosis: role of hepatic and non-hepatic influences.  Eur J Clin Chem Clin Biochem. 1994;  32 749-758
    Google Scholar
  • 45 Müller M J. Ernährung von Leberkranken. Schmidt E, Schmidt FW, Manns MP Lebererkrankungen Pathophysiologie – Diagnostik – Therapie Stuttgart; Wiss. Verl.-Ges 2000: 1080-1104
    Google Scholar
  • 46 Murphy E J, Davern T J, Shakil A O. et al . Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group.  Dig Dis Sci. 2000;  45 549-553
    Google Scholar
  • 47 Nationale Versorgungs-Leitlinie Diabetes mellitus Typ 2.  Z Arztl Fortbild Qualitatssich. 2002;  95 (Suppl 2) 1-23
    Google Scholar
  • 48 Naunyn B. Glykosurie und Diabetes durch experimentelle Insulte und Krankheiten der Leber. Naunyn B Der Diabetes mellitus Vienna, Austria; A. Holder 1898: 38-49
    Google Scholar
  • 49 Niederau C. Diabetes mellitus in hemochromatosis.  Z Gastroenterol. 1999;  Suppl 1 22-32
    Google Scholar
  • 50 Niederau C, Fischer R, Pürschel A. et al . Long-term survival in patients with hereditary hemochromatosis.  Gastroenterology. 1996;  110 1107-1119
    Google Scholar
  • 51 Niederau C, Fischer R, Sonnenberg A. et al . Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.  N Engl J Med. 1985;  14 (313) 1256-1262
    Google Scholar
  • 52 Nishida T, Tsuji S, Tsujii M. et al . Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis.  Am J Gastroenterol. 2006;  101 70-75
    Google Scholar
  • 53 O’Brien T, Barrett B, Murray D M. et al . Usefulness of biochemical screening of diabetic patients for hemochromatosis.  Diabetes Care. 1990;  13 532-534
    Google Scholar
  • 54 Owen O E, Reichle F A, Mozzoli M A. et al . Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis.  J Clin Invest. 1981;  68 240-522
    Google Scholar
  • 55 Panzer S, Kronik G, Lechner K. et al . Glykosylated hemoglobins (GHb): An index of red cell survival.  Blood. 1982;  59 1348-1350
    Google Scholar
  • 56 Papatheodoridis G V, Chrysanthos N, Savvas S. et al . Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis.  Viral Hepat. 2006;  13 303-310
    Google Scholar
  • 57 Perseghini G, Mazzaferro V, Sereni L P. et al . Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation.  Hepatology. 2000;  31 694-703
    Google Scholar
  • 58 Petrides A S. New aspects of the regulation of glucose metabolism in chronic liver diseases.  Z Gastroenterol. 1993;  31 (Suppl 5) 53-55
    Google Scholar
  • 59 Petrides A S. Hepatogenic diabetes: pathophysiology, therapeutic options and prognosis.  Z Gastroenterol. 1999;  Suppl 1 15-21
    Google Scholar
  • 60 Petrides A S, DeFronzo R A. Glucose metabolism in cirrhosis: a review with some perspectives for the future.  Diabetes Metab Rev. 1989;  5 691-709
    Google Scholar
  • 61 Petrides A S, Vogt C, Schulze-Berge D. et al . Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis.  Hepatology. 1994;  19 616-627
    Google Scholar
  • 62 Pirlich M, Lochs H, Ockenga J. Enteral nutrition.  Internist. 2006;  47 405-422
    Google Scholar
  • 63 Plauth M, Ferenci P, Holm E. et al . DGEM-Leitlinie Enterale Ernährung: Hepatologie.  Aktuel Ernähr Med. 2003;  Suppl 1 S87-S92
    Google Scholar
  • 64 Plauth M, Cabre E, Riggio O. et al . ESPEN Guidelines on Enteral Nutrition: Liver disease.  Clin Nutr. 2006;  25 285-294
    Google Scholar
  • 65 Plauth M, Merli M, Kondrup J. et al . ESPEN guidelines for nutrition in liver disease and transplantation.  Clin Nutr. 1997;  16 43-55
    Google Scholar
  • 66 Prijatmoko D, Strauss B J, Lambert J R. et al . Early detection of protein depletion in alcoholic cirrhosis: role of body composition analysis.  Gastroenterology. 1993;  105 1839-1845
    Google Scholar
  • 67 Proietto J, Dudley F J, Aitken P. et al . Hyperinsulinaemia and insulin resistance of cirrhosis: the importance of insulin hypersecretion.  Clin Endocrinol. 1984;  21 657-665
    Google Scholar
  • 68 Promrat K, Lutchman G, Uwaifo G I. et al . A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.  Hepatology. 2004;  39 188-196
    Google Scholar
  • 69 Pugliese D, Lee S S, Koshy A. et al . Systemic and splanchnic hemodynamic effects of intravenous hypertonic glucose in patients with cirrhosis.  Hepatology. 1988;  8 643-646
    Google Scholar
  • 70 Riggio O, Merli M, Cantafora A. et al . Total and individual free fatty acid concentrations in liver cirrhosis.  Metabolism. 1984;  33 646-651
    Google Scholar
  • 71 Sakaida I, Tsuchiya M, Okamoto M. et al . Late evening snack and the change of blood glucose level in patients with liver cirrhosis.  Hepatol Res. 2004;  30 S 67-72
    Google Scholar
  • 72 Sarin S K, Dhingra N, Bansal A. et al . Dietary and nutritional abnormalities in alcoholic liver disease: a comparison with chronic alcoholics without liver disease.  Am J Gastroenterol. 1997;  92 777-783
    Google Scholar
  • 73 Schiefke I, Fach A, Wiedmann M. et al . Reduced bone mineral density et altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection.  World J Gastroenterol. 2005;  11 1843-1847
    Google Scholar
  • 74 Schnedl W J, Wallner S J, Piswanger C. et al . Glycated hemoglobin and liver disease in diabetes mellitus.  Wien Med Wochenschr. 2005;  155 411-415
    Google Scholar
  • 75 Shankbar T P, Solomon S S, Duckworth W C. et al . Growth hormone and carbohydrate intolerance in cirrhosis.  Horm Metab Res. 1988;  20 579-583
    Google Scholar
  • 76 Shetty A, Wilson S, Kuo P. et al . Liver transplantation improves cirrhosis-associated impaired oral glucose tolerance.  Transplantation. 2000;  69 2451-2454
    Google Scholar
  • 77 Siegel E G, Gallwitz B, Schmidt W E. et al . Hepatogenic diabetes – the current concepts of its pathophysiology and therapy.  Dtsch Med Wochenschr. 1999;  124 1530-1535
    Google Scholar
  • 78 Siegel E G, Jakobs R, Riemann J F. Pancreatic insufficiency-induced and hepatogenic diabetes. Special aspects in pathophysiology and treatment.  Internist. 2001;  42 (Suppl 1) 8-19
    Google Scholar
  • 79 Sigal S H, Stanca C M, Kontorinis N. et al . Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis.  Am J Gastroenterol. 2006;  101 1490-1496
    Google Scholar
  • 80 Smith-Laing G, Orskov H, Gore M BR. et al . Hyperglucagonaemia in cirrhosis. Relationship to hepatocellular damage.  Diabetologia. 1980;  19 103-108
    Google Scholar
  • 81 Tilg H, Wilmer A, Vogel W. et al . Serum levels of cytokines in chronic liver diseases.  Gastroenterology. 1992;  103 264-274
    Google Scholar
  • 82 Tsuchiya M, Sakaida I, Okamoto M. et al . The effect of a late evening snack in patients with liver cirrhosis.  Hepatol Res. 2005;  31 95-103
    Google Scholar
  • 83 Unger R H, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes.  Diabetologia. 1985;  28 119-121
    Google Scholar
  • 84 Uribe M, Dibildox M, Malpica S. et al . Beneficial effect of vegetable protein diet supplemented with psyllium plantago in patients with hepatic encephalopathy and diabetes mellitus.  Gastroenterology. 1985;  88 901-907
    Google Scholar
  • 85 Vidal J, Ferrer J P, Esmatjes E. et al . Diabetes mellitus in patients with liver cirrhosis.  Diabetes Res Clin Pract. 1994;  25 19-25
    Google Scholar
  • 86 Wettstein M, Kircheis G, Häussinger D. Hepatische Enzephalopathie – Diagnostik.  Dtsch Med Wochenschr. 2003;  128 2654-2657
    Google Scholar
  • 87 Wyke R J. Problems of bacterial infection in patients with liver disease.  Gut. 1987;  28 623-641
    Google Scholar

Dr. Felix Gundling

II. Medizinische Abteilung Städtisches Krankenhaus München-Bogenhausen

Englschalkinger Straße 77

81925 München

Phone: + + 49/89/92 70 20 61

Fax: + + 49/89/92 70 24 86

Email: Felix.Gundling@gmx.de